GLP-3 (RETA)

from $80.00

Investigational synthetic peptide designed as a triple agonist of the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Engineered for enhanced receptor selectivity and metabolic stability, GLP-3 represents a novel class of incretin-based therapeutics currently under active investigation for its multifaceted role in energy balance, glucose regulation, and adiposity.

Vial Size:

Investigational synthetic peptide designed as a triple agonist of the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Engineered for enhanced receptor selectivity and metabolic stability, GLP-3 represents a novel class of incretin-based therapeutics currently under active investigation for its multifaceted role in energy balance, glucose regulation, and adiposity.